140 related articles for article (PubMed ID: 37517683)
1. Pathogenesis of myopic choroidal neovascularization: A systematic review and meta-analysis.
Zhang XJ; Chen XN; Tang FY; Szeto S; Ling XT; Lin ZX; Tham CC; Pang CP; Chen LJ; Yam JC
Surv Ophthalmol; 2023; 68(6):1011-1026. PubMed ID: 37517683
[TBL] [Abstract][Full Text] [Related]
2. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia.
Ohno-Matsui K; Yoshida T; Futagami S; Yasuzumi K; Shimada N; Kojima A; Tokoro T; Mochizuki M
Br J Ophthalmol; 2003 May; 87(5):570-3. PubMed ID: 12714395
[TBL] [Abstract][Full Text] [Related]
3. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
[TBL] [Abstract][Full Text] [Related]
4. Long-term pattern of progression of myopic maculopathy: a natural history study.
Hayashi K; Ohno-Matsui K; Shimada N; Moriyama M; Kojima A; Hayashi W; Yasuzumi K; Nagaoka N; Saka N; Yoshida T; Tokoro T; Mochizuki M
Ophthalmology; 2010 Aug; 117(8):1595-611, 1611.e1-4. PubMed ID: 20207005
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and Diagnosis of Myopic Choroidal Neovascularization in Asia.
Chan NS; Teo K; Cheung CM
Eye Contact Lens; 2016 Jan; 42(1):48-55. PubMed ID: 26448447
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
7. Choroidal thickness and high myopia: a cross-sectional study and meta-analysis.
Wang S; Wang Y; Gao X; Qian N; Zhuo Y
BMC Ophthalmol; 2015 Jul; 15():70. PubMed ID: 26138613
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
9. Progression of Myopic Maculopathy during 18-Year Follow-up.
Fang Y; Yokoi T; Nagaoka N; Shinohara K; Onishi Y; Ishida T; Yoshida T; Xu X; Jonas JB; Ohno-Matsui K
Ophthalmology; 2018 Jun; 125(6):863-877. PubMed ID: 29371011
[TBL] [Abstract][Full Text] [Related]
10. The correlation of atrophy, traction and neovascularization in myopic choroidal neovascularization according to a novel myopic maculopathy classification system (atrophy (A), traction (T), neovascularization (N): ATN).
Kurt RA; Sarıgül Sezenöz A; Akkoyun I; Yılmaz G
Int Ophthalmol; 2022 Sep; 42(9):2925-2932. PubMed ID: 35876940
[TBL] [Abstract][Full Text] [Related]
11. The types and severity of high myopic maculopathy in Chinese patients.
Chen H; Wen F; Li H; Zuo C; Zhang X; Huang S; Luo G
Ophthalmic Physiol Opt; 2012 Jan; 32(1):60-7. PubMed ID: 21762440
[TBL] [Abstract][Full Text] [Related]
12. Choroidal thickness after treatment for myopic
choroidal neovascularization.
Farinha CL; Baltar AS; Nunes SG; Franqueira NF; Figueira JP; Pires IA; Cachulo ML; Silva RM
Eur J Ophthalmol; 2013; 23(6):887-98. PubMed ID: 23787449
[TBL] [Abstract][Full Text] [Related]
13. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
14. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
15. Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study.
Kang HM; Koh HJ
Retina; 2013 Sep; 33(8):1613-22. PubMed ID: 23591527
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia.
Miyake M; Yamashiro K; Akagi-Kurashige Y; Kumagai K; Nakata I; Nakanishi H; Oishi A; Tsujikawa A; Yamada R; Matsuda F; Yoshimura N
Ophthalmology; 2014 Jan; 121(1):225-233. PubMed ID: 23953100
[TBL] [Abstract][Full Text] [Related]
18. [Macular choroidal thickness assessment with SD-OCT in high myopia with or without choroidal neovascularization].
El Matri L; Bouladi M; Chebil A; Kort F; Largueche L; Mghaieth F
J Fr Ophtalmol; 2013 Oct; 36(8):687-92. PubMed ID: 23896210
[TBL] [Abstract][Full Text] [Related]
19. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
[TBL] [Abstract][Full Text] [Related]
20. Progression of myopic maculopathy after treatment of choroidal neovascularization.
Farinha CL; Baltar AS; Nunes SG; Figueira JP; Pires IA; Cachulo ML; Silva RM
Ophthalmologica; 2014; 231(4):211-20. PubMed ID: 24662778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
